Has Rebecca Sandler, MD received payments from drug or device companies?

Yes. Drug and device makers reported $490 in general payments to Rebecca Sandler, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rebecca Sandler, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rebecca Sandler, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rebecca Sandler, MD

Endocrinology, Diabetes & Metabolism · Clifton, NJNPI 1831394527

Payments from drug & device makers

$490in general payments, 2019–2025

Across 6 payments — averaging $81.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Tandem Diabetes Care, Inc.$300
Shire North American Group Inc$102
Medtronic$64
Lilly USA, LLC$24

What the payments were for

Speaking & faculty fees$30061%
Food & beverage$17836%
Education$122%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Tandem Diabetes Care, Inc.	1	$300
Shire North American Group Inc	1	$102
Medtronic	2	$64
Lilly USA, LLC	2	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

t:slim X2 insulin pump$300
NATPARA (PARATHYROID HORMONE)$102

How this compares

$490 in reported general payments places this provider in the 20th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$297,587

Medicare patients

473

Services billed

9,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	279	$494,668
MounjaroTirzepatide	334	$468,717
JardianceEmpagliflozin	135	$164,239
TrulicityDulaglutide	88	$159,966
FarxigaDapagliflozin Propanediol	104	$125,058
Tresiba Flextouch U-200Insulin Degludec	78	$82,517
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	67	$56,594
TradjentaLinagliptin	53	$55,082
Tresiba Flextouch U-100Insulin Degludec	84	$54,801
Humalog Kwikpen U-200Insulin Lispro	15	$37,285
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	17	$36,936
RybelsusSemaglutide	22	$35,677
Janumet XrSitagliptin Phos/Metformin Hcl	37	$32,799
Xigduo XrDapaglifloz Propaned/Metformin	36	$31,222
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	67	$30,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog	$24	$636,051441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Clifton

Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Marc SandbergFlemington$567K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Taher ModarressiPennington$414K
Navtika DesaiHillsborough$408K
Atara SchultzTeaneck$357K
Anthony CannonTurnersville$296K
Sunil AsnaniBrick$295K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →